Wealthstream Advisors Inc. Buys Shares of 93,906 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Wealthstream Advisors Inc. bought a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) in the first quarter, Holdings Channel.com reports. The firm bought 93,906 shares of the company’s stock, valued at approximately $378,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Endurance Wealth Management Inc. lifted its position in Ginkgo Bioworks by 100.0% during the first quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company’s stock valued at $40,000 after purchasing an additional 5,000 shares during the period. Financial Consulate Inc. acquired a new stake in Ginkgo Bioworks during the first quarter worth about $40,000. IHT Wealth Management LLC purchased a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $91,000. Qube Research & Technologies Ltd acquired a new position in Ginkgo Bioworks in the fourth quarter valued at approximately $92,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Ginkgo Bioworks during the 1st quarter valued at about $54,000. Institutional investors and hedge funds own 46.93% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DNA. Bank of America downgraded shares of Ginkgo Bioworks from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research report on Wednesday, May 18th. BTIG Research raised their price target on Ginkgo Bioworks from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Tuesday. Jefferies Financial Group lowered their target price on Ginkgo Bioworks from $11.50 to $4.35 in a research note on Thursday, June 16th. Finally, Raymond James increased their target price on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the company an “outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.69.

Ginkgo Bioworks Trading Down 9.6 %

NYSE:DNA traded down $0.36 during mid-day trading on Wednesday, hitting $3.38. The company had a trading volume of 1,327,776 shares, compared to its average volume of 26,275,532. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.66 and a current ratio of 10.71. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $2.09 and a fifty-two week high of $15.86. The firm has a market cap of $6.01 billion, a P/E ratio of -1.78 and a beta of 1.93. The business’s fifty day moving average is $2.91 and its two-hundred day moving average is $3.45.

Ginkgo Bioworks (NYSE:DNAGet Rating) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.38). Ginkgo Bioworks had a negative net margin of 549.38% and a negative return on equity of 46.88%. As a group, research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -0.12 earnings per share for the current year.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Further Reading

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating).

Institutional Ownership by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.